



EAST LANCASHIRE HEALTH ECONOMY MEDICINES MANAGEMENT BOARD

MINUTES OF THE TEAMS MEETING 15TH JULY 2020

PRESENT:

Dr L Rogan (LR)	Strategic Director of Medicines, Research and Clinical Effectiveness NHS EL CCG (Acting Chairperson)
Mr N Fletcher (NF)	Director of Pharmacy ELHT
Mrs C Woffindin (CW)	Medicines Information Manager, ELHT
Dr S Jackson (SJ)	Clinical Commissioning Group MM Lead, GP EL
Dr T McKenzie (TM)	GP East Lancs
Mr J Vaughan (JV)	Commissioning Support Pharmacist NHS EL/BwD
Mrs C Dugdale (CD)	Meds Management Pharmacist NHS BwD CCG
Mr A Gray (AG)	Clinical Pharmacist, ELHT
Mr U Akram	Pharmacist, Lancashire Care Foundation Trust
Dr J Adiyodi (JA)	Consultant Haematologist, ELHT (part of meeting)

IN ATTENDANCE:

Ms L Prince	Medicines Management Technician, EL CCG
Ms E White	Tissue Viability Nurse Specialist
Dr I Hafeez	Consultant Respiratory Physician, ELNT

2020/057: APOLOGIES:

Mr V Goodey (VG)	Assistant Director of Pharmacy, Clin Service ELHT
Dr R Ahmed (RA)	GP BwD CCG
Dr Duncan Gavan	Consultant Radiologist, ELHT

2020/058: DECLARATION OF INTEREST

None declared – relevant to agenda items.

2020/059: MINUTES OF JUNE Teams MEETING:

On page 1 item 2019/131 it should say 'active' instead of 'live' B12 testing.
Otherwise accepted as a correct record.

2020/060: MATTERS ARISING:

2019/131: Treatment of Vitamin B12 Deficiency Draft – A pathway is currently being developed with Jane Oakey from Path Lab who is exploring options re. active B12 testing in the lab. LR to obtain update on progress. To be brought to ELMMB when completed.

2020/020: Formulary Updates - Ranolazine & Ivabradine – Dr Singh to assist with producing a Hot Topic to support GP prescribing. JV to follow up.

2020/031: NICE Recommendations (from Feb) – Patiromer – Red Traffic light suggested but to check with renal physicians and also status in Central Lancashire.

2020/044: New Product Request – Wavesense Jazz BGT Strips – the use of the Wavesense JAZZ meter and strips was requested to facilitate remote management of blood glucose in gestational diabetes. The remote management will initially be free for the 12 month project and if successful a business case will be required to be written and approved for continuation of use. Family care division have liaised with diabetes service and both are keen to proceed with the project. ELMMB agreed to the addition of Wavesense JAZZ BGT strips to formulary for use with the Wavesense JAZZ meter, in gestational diabetes, initially for 12 months then review is required.

Resolved: Wavesense JAZZ BGT Strips added to formulary for use with the Wavesense JAZZ meter in gestational diabetes.

2020/048: Formulary Updates: Combination diabetes products – discussed with primary care diabetes specialists with some variation in opinions. ELMMB members expressed concerns over lack of dosing flexibility, difficulties identifying cause of adverse effects and need to stop combination products rather than just metformin when implementing sick day rules. Following a lengthy discussion, ELMMB agreed that combination diabetes products would not be included in the formulary. Any use should be by exception only.

Resolved: Combination diabetes products will not be included on formulary.

2020/049: Managed Introduction of New Drugs Policy – No further comments received and has been sent to CCG Board for ratification. NF to send to trust board for ratification.

2020/015: New Product Request – Relvar Ellipta® & Anoro Ellipta®

Dr Hafeez, Respiratory consultant in attendance for this item.

Anoro Ellipta® has been requested as a dry powder LAMA+LABA option for COPD for patients to offer consistency of device when stepping up/down to/from Trelegy Ellipta®. Relvar Ellipta® has also been requested as an alternative dry powder device for asthma. On the current asthma guidelines fluticasone (as propionate) containing devices are not currently included. The Relvar Ellipta® device contains fluticasone as furoate with vilanterol and has reported fewer adverse effects compared with other high dose fluticasone propionate devices available.

It poses a challenge to GPs when patients are seen out of area and commenced on these products and also for the hospital when patients are admitted on non-formulary products. The DH is also encouraging use of DPIs rather than MDIs from an environmental perspective however Relvar is not licensed for using in MART regimens. ELMMB members agreed to add the two devices to formulary for initiation in secondary care. JV to arrange a meeting with Dr Hafeez, to consider their place in the primary care guidelines, and bring back to ELMMB.

Resolved: Relvar Ellipta® and Anoro Ellipta® added to formulary for initiation in secondary care.

Traffic Light: AMBER

Action: JV to arrange meeting to consider their place on primary care guidelines.

2020/055: For Action/Information: LSCFT Drug & Therapeutics Committee Minutes Mar 2020 – Lamotrigine now licensed for bipolar – LSCFT have confirmed there is no specific monitoring for lamotrigine for bipolar and refer to their SOP for monitoring of psychotropic medication for routine monitoring. Include on formulary as a mood stabiliser in bipolar disease with Amber traffic light.

Resolved: Bipolar indication for lamotrigine included on formulary.

Traffic Light: AMBER

Deferred Item

2020/041: NEW PRODUCT REQUEST – CAVILON ADVANCED (& MEDI DERMA RANGE)

Liz White, Tissue Viability Specialist Nurse in attendance for this item.

Moisture associated skin damage management has moved to Medi Derma range as one of previous cream/ barrier film options is no longer available. The Pro Shield spray cleanser and skin protectant will also change to the Medi Derma Pro cleanser and ointment (available via NHS supplies).

Cavilon Advanced skin protectant is requested for addition to wound care formulary for severe skin damage, including painful skin stripping that is not responding to first line options. It reduces the time to healing of excoriated skin as well as decreasing associated pain. It would be restricted to critical care, gastro wards & small number of other patients and only on the advice of the tissue viability nurses. ELMMB members agreed to add to wound care formulary. It will be available via pharmacy.

Resolved: Cavilon Advanced Skin Protectant included in Wound Care Formulary on advice of tissue viability nurses only.

Traffic Light: AMBER

New Items

2020/061: LSCMMG CONSULTATIONS (FOR AUGUST LSCMMG)

Primary Care Management of Neuropathic Pain Pathway – it is not clear if this one page flow diagram taken from NICE guidance is to replace or complement the original more detailed pathway. To confirm with LSCMMG.

Pregabalin for GAD New Medicines Assessment – the evidence indicates efficacy at higher doses. There are however concerns with length of course, high dependence/abuse potential & stopping. Patients with GAD often have long waits for specialist appointments. ELMMB members considered that Amber was potentially the most appropriate traffic light but could be available in exceptional cases if there was a clear pathway for its use and a shared care agreement.

Melatonin in RBD in Parkinson's disease New Medicines Assessment – melatonin for this indication is included in NICE guidance. Support the recommendation and suggest it would be second line after clonazepam and that neurologist should review for effectiveness after one - three months.

Pneumococcal Vaccine for Respiratory Conditions New Medicines Assessment – The recommendation did not appear to address the indication that the review was requested for. The respiratory consultants are recommending it as a test of the immune system with functional antibody testing as referenced in BTS guidelines.

Dibotermin alfa New Medicine Assessment – requests have come from other centres for use in non-union long bone fractures which is not a licensed indication. Recommendation of red for licensed indication and black for unlicensed indication supported.

Resolved: Comments to be sent to LSCMMG.

2020/062: LSCMMG Recommendations

No meeting in June

2020/063: JOINT COMMITTEE OF CCGs COMMISSIONING DECISIONS

No meetings.

2020/064: FORMULARY UPDATES

Exocream – cost effective equivalent to E45 cream. Agreed to add to formulary.

Resolved: Formulary to be updated as above

2020/065: ELHT: POLICY AND PROCEEDURE FOR THE T34 AMBULATORY SYRINGE PUMP IN ADULTS (PALLIATIVE CARE) UPDATED

A minor update included with a full review due next month. Acknowledged

Resolved: Updated document acknowledged.

2020/066: NICE RECOMMENDATIONS (from June)

Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure [TA626] is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned

Traffic Light: RED

Fremanezumab for preventing migraine (TA631) is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned BlueTeq form required

Traffic Light: RED

Trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632) is recommended as an option by NICE. Approved in line with NICE.

NHS England Commissioned

Traffic Light: RED

Ustekinumab for treating moderately to severely active ulcerative colitis [TA633] is recommended as an option by NICE. Approved in line with NICE.

CCG Commissioned BlueTeq form required

Traffic Light: RED

Daratumumab with lenalidomide and dexamethasone for untreated multiple myeloma (terminated appraisal) (TA634)

Traffic Light: BLACK

Ramucirumab with erlotinib for untreated EGFR-positive metastatic non-small-cell lung cancer (terminated appraisal) (TA635) **Traffic Light: BLACK**

Eculizumab for treating refractory myasthenia gravis (terminated appraisal) (TA636) **Traffic Light: BLACK**

Ranibizumab for treating diabetic retinopathy (terminated appraisal) (TA637) **Traffic Light: BLACK**

2020/067: EAMS: ATEZOLIZUMAB

Atezolizumab, in combination with bevacizumab, is indicated for the treatment of adult patients with a cancer that affects the liver called hepatocellular carcinoma (HCC), which cannot be treated by removing the affected portion of the liver and when no other specific medicines have been given for this cancer.

Resolved: EAMS Atezolizumab acknowledged

STANDING ITEMS

2020/068: FOR ACTION/INFORMATION: LANCASHIRE & SOUTH CUMBRIA MEDICINES MANAGEMENT GROUP (LSCMMG) MINUTES -

No meeting in June

DATE OF NEXT MEETING – Wednesday 19th August 2020 12.30pm via ‘Microsoft Teams’

**ACTION SHEET FROM
EAST LANCASHIRE HEALTH ECONOMY
MEDICINES MANAGEMENT BOARD**

WEDNESDAY 15th JULY 2020

MINUTE NUMBER	DESCRIPTION	ACTION	DATE
2019/131	Treatment Of Vitamin B12 Deficiency Draft – pathway to be developed. Check on progress	LR/JV LR	Feb 20 Sept 20
2020/015	New Product request – Relvar Ellipta® & Anoro Ellipta® - meeting to be arranged to consider place on primary care guidelines	JV	Sept 20
2020/020	Formulary Updates – Ranolazine & Ivabradine – Hot Topic to support GP prescribing to be produced with assistance from Dr Singh Follow up with Dr Singh	JV JV	Apr 20 Aug 20
2020/031	NICE RECOMMENDATIONS (from Feb) – Patiromer – check traffic light with renal physicians and Central Lancs	CW	Jul 20